EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505

Jordan M Cloyd, Sarah Colby, Katherine A Guthrie, Andy M Lowy, E Gabrielle Chiorean, Phillip Philip, Davendra Sohal, Syed Ahmad

Journal of the National Comprehensive Cancer Network · 2024-05 · 22 (4)

DOI: 10.6004/jnccn.2023.7099 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2024-05. Verfasst von Jordan M Cloyd und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Pancreatic Neoplasms, Pancreatectomy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neoadjuvant therapy (NT) is increasingly used for patients with pancreatic ductal adenocarcinoma (PDAC), and yet reasons for not undergoing subsequent pancreatectomy are poorly understood. Given the importance of completing multimodality therapy, we investigated factors associated with failure to undergo surgical resection following NT for PDAC.

Methods

SWOG S1505 was a multicenter phase II randomized trial of preoperative mFOLFIRINOX or gemcitabine/nab-paclitaxel prior to planned pancreatectomy for patients with potentially resectable PDAC. Associations between clinical, demographic, and hospital-level characteristics and receipt of surgical resection were estimated via multiple logistic regression. Differences in overall survival from 18 weeks postrandomization (scheduled time of surgery) according to resection status were assessed via Cox regression models.

Results

Among 102 eligible patients, 73 (71.6%) underwent successful pancreatectomy, whereas 29 (28.4%) did not, primarily because of progression (n=11; 10.8%) or toxicity during NT (n=9; 8.8%). Weight loss during NT (odds ratio [OR], 0.34; 95% CI, 0.11–0.93) and the hospital’s city size (small: OR, 0.24 [95% CI, 0.07–0.80] and large: OR, 0.28 [95% CI, 0.10–0.79] compared with midsize) were significantly associated with a lower probability of surgical resection in adjusted models, whereas age, sex, race, body mass index, performance status, insurance type, geographic region, treatment arm, tumor location, chemotherapy delays/modifications, and hospital characteristics were not. Surgical resection following NT was associated with improved overall survival (median, 23.8 vs 10.8 months; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyPancreatic NeoplasmsPancreatectomyAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedAgedLeucovorinCarcinoma, Pancreatic DuctalPaclitaxelFluorouracilIrinotecanOxaliplatinDeoxycytidineGemcitabineAdultAlbumins

Substanzen

LeucovorinPaclitaxelFluorouracilIrinotecanOxaliplatinDeoxycytidineGemcitabineAlbuminsfolfirinox130-nm albumin-bound paclitaxel

Autor:innen und Institutionen

  • Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH.
  • SWOG Statistical and Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA.
  • Department of Surgery, University of California, San Diego, CA.
  • University of Washington School of Medicine, Fred Hutchinson Cancer Center, Seattle, WA.
  • Henry Ford Health, Detroit, Michigan.
  • Division of Hematology and Oncology, University of Cincinnati, Cincinnati, OH.

Förderung

  • NCI NIH HHS

Zitieren

APA

Cloyd, J. M., Colby, S., Guthrie, K. A., Lowy, A. M., Chiorean, E. G., Philip, P., Sohal, D., & Ahmad, S. (2024). Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505. Journal of the National Comprehensive Cancer Network, 22(4). https://doi.org/10.6004/jnccn.2023.7099

Vancouver

Cloyd JM, Colby S, Guthrie KA, Lowy AM, Chiorean EG, Philip P, et al. Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505. Journal of the National Comprehensive Cancer Network. 2024;22(4). doi:10.6004/jnccn.2023.7099

BibTeX
@article{Cloyd2024,
  author = {Cloyd, Jordan M and Colby, Sarah and Guthrie, Katherine A and Lowy, Andy M and Chiorean, E Gabrielle and Philip, Phillip and Sohal, Davendra and Ahmad, Syed},
  title = {Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2024},
  volume = {22},
  number = {4},
  doi = {10.6004/jnccn.2023.7099}
}
Kostenlos starten →